Capricor Therapeutics Announces Follow-Up Type-B Clinical Meeting With The FDA For CAP-1002 For The Treatment Of Duchenne Muscular Dystrophy
Portfolio Pulse from Benzinga Newsdesk
Capricor Therapeutics (NASDAQ:CAPR) announced an upcoming Type-B clinical meeting with the FDA in early Q3 2023 to discuss the proposed path towards submission of a potential Biologics License Application (BLA) for CAP-1002, a treatment for Duchenne muscular dystrophy (DMD). The company expects to complete enrollment for its Phase 3 HOPE-3 clinical trial by the second half of 2023 and report interim analysis in Q4 2023.
June 07, 2023 | 1:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Capricor Therapeutics is set to discuss the proposed path towards submission of a potential BLA for CAP-1002 with the FDA in early Q3 2023. The company expects to complete enrollment for its Phase 3 HOPE-3 clinical trial by the second half of 2023.
The upcoming Type-B clinical meeting with the FDA and the progress in the Phase 3 HOPE-3 clinical trial are positive developments for Capricor Therapeutics. If the FDA approves CAP-1002, it could lead to a new treatment option for DMD, potentially benefiting the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100